Literature DB >> 6489358

Macrophages of athymic nude mice: Fc receptors, C receptors, phagocytic and pinocytic activities.

V Vĕtvicka, L Fornůsek, M Holub, J Zídková, J Kopecek.   

Abstract

Expression of Fc receptors (FcR) for IgG1, IgG2A, IgG2B, IgM, IgA and IgE, binding of C3 and C5 complement components and phagocytic and pinocytic activities were determined in peritoneal and omental macrophages of nu/nu, nu/+ and +/+ Balb/c mice. nu/nu mice showed a higher proportion of FcR and complement receptor-bearing peritoneal macrophages along with a significantly higher phagocytic activity of peritoneal macrophages both in vitro and in vivo. Tests of pinocytic activity in these cells and phagocytic activity in omental phagocytes yielded similar results. We conclude that athymic mice compensate their immune defects by a higher phagocytic activity of their professional phagocytes and a higher expression of receptors mediating this process.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6489358

Source DB:  PubMed          Journal:  Eur J Cell Biol        ISSN: 0171-9335            Impact factor:   4.492


  3 in total

1.  Androgen receptor facilitates the recruitment of macrophages in tumor microenvironment to promote upper urinary tract urothelial cell carcinoma progression.

Authors:  Chi-Cheng Chen; Chi-Ping Huang; Teng-Fu Hsieh; Wei-Kai Chiu; Wen-Ling Chang; Chih-Rong Shyr
Journal:  Am J Cancer Res       Date:  2016-09-01       Impact factor: 6.166

2.  Ephrin A2 receptor targeting does not increase adenoviral pancreatic cancer transduction in vivo.

Authors:  Michael A van Geer; Conny T Bakker; Naoya Koizumi; Hiroyuki Mizuguchi; John G Wesseling; Ronald P J Oude Elferink; Piter J Bosma
Journal:  World J Gastroenterol       Date:  2009-06-14       Impact factor: 5.742

3.  Enhanced transplantability of human ovarian cancer lines in cyclophosphamide-pretreated nude mice.

Authors:  M M Nauta; E Boven; H M Schlüper; C A Erkelens; H M Pinedo
Journal:  Br J Cancer       Date:  1986-08       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.